A revolutionary transformation in biomedical imaging is unfolding with the advent of aggregation-induced emission luminogens (AIEgens). These cutting-edge molecules not only overcome the limitations of traditional fluorescent probes but also improve the boundaries of high-contrast imaging. Unlike conventional fluorophores suffering from aggregation-caused quenching, AIEgens exhibit enhanced luminescence when aggregated, enabling superior imaging performance. This review delves into the molecular mechanisms of aggregation-induced emission (AIE), demonstrating how strategic molecular design unlocks exceptional luminescence and superior imaging contrast, which is crucial for distinguishing healthy and diseased tissues. This review also highlights key applications of AIEgens, such as time-resolved imaging, second near-infrared window (NIR-II), and the advancement of AIEgens in sensitivity to physical and biochemical cue-responsive imaging. The development of AIE technology promises to transform healthcare from early disease detection to targeted therapies, potentially reshaping personalized medicine. This paradigm shift in biophotonics offers efficient tools to decode the complexities of biological systems at the molecular level, bringing us closer to a future where the invisible becomes visible and the incurable becomes treatable.
Keywords: Aggregation-Induced Emission (AIE); High-Contrast Imaging; Molecular Design Strategies; Near-Infrared (NIR-II) Imaging; Personalized Medicine; Responsive Imaging; Theranostics; Time-Resolved (TR) Imaging.